Structural basis for inhibition of Escherichia coli uridine phosphorylase by 5-substituted acyclouridines

被引:22
作者
Bu, WM
Settembre, EC
el Kouni, MH
Ealick, SE [1 ]
机构
[1] Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA
[2] Univ Alabama Birmingham, Ctr Comprehens Canc, Ctr AIDS Res, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA
来源
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY | 2005年 / 61卷
关键词
D O I
10.1107/S0907444905007882
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Uridine phosphorylase (UP) catalyzes the reversible phosphorolysis of uridine to uracil and ribose 1-phosphate and is a key enzyme in the pyrimidine-salvage pathway. Escherichia coli UP is structurally homologous to E. coli purine nucleoside phosphorylase and other members of the type I family of nucleoside phosphorylases. The structures of 5-benzylacyclouridine, 5-phenylthioacyclouridine, 5-phenylselenenylacyclouridine, 5-m-benzyloxybenzyl acyclouridine and 5-m-benzyloxybenzyl barbituric acid acyclonucleoside bound to the active site of E. coli UP have been determined, with resolutions ranging from 1.95 to 2.3 angstrom. For all five complexes the acyclo sugar moiety binds to the active site in a conformation that mimics the ribose ring of the natural substrates. Surprisingly, the terminal hydroxyl group occupies the position of the nonessential 5'-hydroxyl substituent of the substrate rather than the 3'-hydroxyl group, which is normally required for catalytic activity. Until recently, inhibitors of UP were designed with limited structural knowledge of the active-site residues. These structures explain the basis of inhibition for this series of acyclouridine analogs and suggest possible additional avenues for future drug-design efforts. Furthermore, the studies can be extended to design inhibitors of human UP, for which no X-ray structure is available.
引用
收藏
页码:863 / 872
页数:10
相关论文
共 53 条
[1]   Three-dimensional structure of a hyperthermophilic 5′-deoxy-5′-methylthioadenosine phosphorylase from Sulfolobus solfataricus [J].
Appleby, TC ;
Mathews, II ;
Porcelli, M ;
Cacciapuoti, G ;
Ealick, SE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) :39232-39242
[2]   The structure of human 5′-deoxy-5′-methylthioadenosine phosphorylase at 1.7 Å resolution provides insights into substrate binding and catalysis [J].
Appleby, TC ;
Erion, MD ;
Ealick, SE .
STRUCTURE, 1999, 7 (06) :629-641
[3]   Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy [J].
Ashour, OM ;
Al Safarjalani, ON ;
Naguib, FNM ;
Goudgaon, NM ;
Schinazi, RF ;
el Kouni, MH .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (05) :351-361
[4]   Purine nucleoside phosphorylase from Mycobacterium tuberculosis.: Analysis of inhibition by a transition-state analogue and dissection by parts [J].
Basso, LA ;
Santos, DS ;
Shi, WX ;
Furneaux, RH ;
Tyler, PC ;
Schramm, VL ;
Blanchard, JS .
BIOCHEMISTRY, 2001, 40 (28) :8196-8203
[5]   Designer gene therapy using an Escherichia coli purine nudeloside phosphorylase/prodrug system [J].
Bennett, EM ;
Anand, R ;
Allan, PW ;
Hassan, AEA ;
Hong, JS ;
Levasseur, DN ;
McPherson, DT ;
Parker, WB ;
Secrist, JA ;
Sorscher, EJ ;
Townes, TM ;
Waud, WR ;
Ealick, SE .
CHEMISTRY & BIOLOGY, 2003, 10 (12) :1173-1181
[6]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[7]  
Burling FT, 2003, ACTA CRYSTALLOGR D, V59, P73, DOI [10.1107/S0907444902018929, 10.1107/s0907444902018929]
[8]   Crystal structures of Escherichia coli uridine phosphorylase in two native and three complexed forms reveal basis of substrate specificity, induced conformational changes and influence of potassium [J].
Caradoc-Davies, TT ;
Cutfield, SM ;
Lamont, IL ;
Cutfield, JF .
JOURNAL OF MOLECULAR BIOLOGY, 2004, 337 (02) :337-354
[9]  
CHA S, 1989, Yonsei Medical Journal, V30, P315
[10]   INHIBITOR PROPERTIES OF SOME 5-SUBSTITUTED URACIL ACYCLONUCLEOSIDES, AND 2,2'-ANHYDROURIDINES VERSUS URIDINE PHOSPHORYLASE FROM ESCHERICHIA-COLI AND MAMMALIAN SOURCES [J].
DRABIKOWSKA, AK ;
LISSOWSKA, L ;
VERES, Z ;
SHUGAR, D .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (23) :4125-4128